277 related articles for article (PubMed ID: 30848956)
41. Universal Lynch Syndrome Screening Should be Performed in All Upper Tract Urothelial Carcinomas.
Ju JY; Mills AM; Mahadevan MS; Fan J; Culp SH; Thomas MH; Cathro HP
Am J Surg Pathol; 2018 Nov; 42(11):1549-1555. PubMed ID: 30148743
[TBL] [Abstract][Full Text] [Related]
42. A novel complex mutation in MSH2 contributes to both Muir-Torre and Lynch Syndrome.
Perera S; Ramyar L; Mitri A; Pollett A; Gallinger S; Speevak MD; Aronson M; Bapat B
J Hum Genet; 2010 Jan; 55(1):37-41. PubMed ID: 19911012
[TBL] [Abstract][Full Text] [Related]
43. DNA mismatch repair and Lynch syndrome.
Plotz G; Zeuzem S; Raedle J
J Mol Histol; 2006 Sep; 37(5-7):271-83. PubMed ID: 16821093
[TBL] [Abstract][Full Text] [Related]
44. Utility of immunohistochemistry for mismatch repair proteins on colorectal polyps in the familial cancer clinic.
Dow E; Buchanan DD; Winship IM
Intern Med J; 2018 Nov; 48(11):1325-1330. PubMed ID: 29717530
[TBL] [Abstract][Full Text] [Related]
45. [Clinicopathological screening of Lynch syndrome: a report of 2 cases and literature review].
Si JW; Wang L; Ba XJ; Zhang X; Dong Y; Zhang JX; Li WT; Li T
Beijing Da Xue Xue Bao Yi Xue Ban; 2015 Oct; 47(5):858-64. PubMed ID: 26474631
[TBL] [Abstract][Full Text] [Related]
46. [Lynch Syndrome - the Pathologist's Diagnosis].
Dušek M; Hadravský L; Černá K; Stehlík J; Švajdler M; Kokošková B; Dubová M; Michal M; Daum O
Klin Onkol; 2016; 29(3):180-6. PubMed ID: 27296402
[TBL] [Abstract][Full Text] [Related]
47. Interpretation of immunohistochemistry for mismatch repair proteins is only reliable in a specialized setting.
Overbeek LI; Ligtenberg MJ; Willems RW; Hermens RP; Blokx WA; Dubois SV; van der Linden H; Meijer JW; Mlynek-Kersjes ML; Hoogerbrugge N; Hebeda KM; van Krieken JH
Am J Surg Pathol; 2008 Aug; 32(8):1246-51. PubMed ID: 18677806
[TBL] [Abstract][Full Text] [Related]
48. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
[TBL] [Abstract][Full Text] [Related]
49. Targeted Next-Generation Sequencing for Hereditary Cancer Syndromes: A Focus on Lynch Syndrome and Associated Endometrial Cancer.
Tafe LJ
J Mol Diagn; 2015 Sep; 17(5):472-82. PubMed ID: 26162329
[TBL] [Abstract][Full Text] [Related]
50. Universal Point of Care Testing for Lynch Syndrome in Patients with Upper Tract Urothelial Carcinoma.
Metcalfe MJ; Petros FG; Rao P; Mork ME; Xiao L; Broaddus RR; Matin SF
J Urol; 2018 Jan; 199(1):60-65. PubMed ID: 28797715
[TBL] [Abstract][Full Text] [Related]
51. Detection of DNA repair protein in colorectal cancer of patients up to 50 years old can increase the identification of Lynch syndrome?
Germini DE; Mader AM; Gomes LG; Teodoro TR; Franco MI; Waisberg J
Tumour Biol; 2016 Feb; 37(2):2757-64. PubMed ID: 26408182
[TBL] [Abstract][Full Text] [Related]
52. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients.
Hampel H; Frankel W; Panescu J; Lockman J; Sotamaa K; Fix D; Comeras I; La Jeunesse J; Nakagawa H; Westman JA; Prior TW; Clendenning M; Penzone P; Lombardi J; Dunn P; Cohn DE; Copeland L; Eaton L; Fowler J; Lewandowski G; Vaccarello L; Bell J; Reid G; de la Chapelle A
Cancer Res; 2006 Aug; 66(15):7810-7. PubMed ID: 16885385
[TBL] [Abstract][Full Text] [Related]
53. Lynch syndrome in the 21st century: clinical perspectives.
Tiwari AK; Roy HK; Lynch HT
QJM; 2016 Mar; 109(3):151-8. PubMed ID: 26224055
[TBL] [Abstract][Full Text] [Related]
54. Immunohistochemical evaluation of mismatch repair proteins in colorectal carcinoma: the AIFEG/GIPAD proposal.
Remo A; Fassan M; Lanza G
Pathologica; 2016 Sep; 108(3):104-109. PubMed ID: 28195261
[TBL] [Abstract][Full Text] [Related]
55. Universal Versus Targeted Screening for Lynch Syndrome: Comparing Ascertainment and Costs Based on Clinical Experience.
Erten MZ; Fernandez LP; Ng HK; McKinnon WC; Heald B; Koliba CJ; Greenblatt MS
Dig Dis Sci; 2016 Oct; 61(10):2887-2895. PubMed ID: 27384051
[TBL] [Abstract][Full Text] [Related]
56. Microsatellite instability and colorectal cancer.
Geiersbach KB; Samowitz WS
Arch Pathol Lab Med; 2011 Oct; 135(10):1269-77. PubMed ID: 21970482
[TBL] [Abstract][Full Text] [Related]
57. Lynch Syndrome Genetics and Clinical Implications.
Peltomäki P; Nyström M; Mecklin JP; Seppälä TT
Gastroenterology; 2023 Apr; 164(5):783-799. PubMed ID: 36706841
[TBL] [Abstract][Full Text] [Related]
58. RNF43 is mutated less frequently in Lynch Syndrome compared with sporadic microsatellite unstable colorectal cancers.
Fennell LJ; Clendenning M; McKeone DM; Jamieson SH; Balachandran S; Borowsky J; Liu J; Kawamata F; Bond CE; Rosty C; Burge ME; Buchanan DD; Leggett BA; Whitehall VLJ
Fam Cancer; 2018 Jan; 17(1):63-69. PubMed ID: 28573495
[TBL] [Abstract][Full Text] [Related]
59. Germline MLH1 Mutations Are Frequently Identified in Lynch Syndrome Patients With Colorectal and Endometrial Carcinoma Demonstrating Isolated Loss of PMS2 Immunohistochemical Expression.
Dudley B; Brand RE; Thull D; Bahary N; Nikiforova MN; Pai RK
Am J Surg Pathol; 2015 Aug; 39(8):1114-20. PubMed ID: 25871621
[TBL] [Abstract][Full Text] [Related]
60. [Should we systematically screen for Lynch syndrome in patients with upper urinary tract carcinoma?].
Olagui GS; Pignot G; Rouquette A; Vieillefond A; Amsellem-Ouazana D; de Longchamps NB; Radenen B; Zerbib M; Terris B
Bull Cancer; 2014 Feb; 101(2):144-50. PubMed ID: 24556207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
